Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.51 |
| ▸ | EDNRA | P25101 | 1/20 | 0.51 |
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PFKFB4 | Q16877 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21124780 | 0.79 | EDNRB (0.49) | EDNRBEDNRAPFKFB3MMP1MMP13 | |
| SCHEMBL28559447 | 0.76 | HTT (0.48) | MAPT | |
| SCHEMBL22012739 | 0.74 | PLK1 (0.36) | EDNRBEDNRAMAPT | |
| SCHEMBL22014857 | 0.74 | HPGD (0.33) | EDNRBEDNRAMAPT | |
| SCHEMBL22014873 | 0.74 | L3MBTL1 (0.33) | PFKFB3MAPT | |
| SCHEMBL23569180 | 0.74 | L3MBTL1 (0.33) | MAPT | |
| SCHEMBL10680402 | 0.73 | KEAP1 (0.48) | EDNRBEDNRAMMP1MMP13NR3C2 | |
| SCHEMBL21962564 | 0.72 | EDNRB (0.41) | EDNRBEDNRAPFKFB3MMP1MMP13 | |
| SCHEMBL25034034 | 0.71 | ALDH1A1 (0.35) | MAPT | |
| SCHEMBL25794370 | 0.71 | NLRP3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | EDNRB 705/4885EDNRA 388/4885PFKFB3 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.